Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation
Nasr El-Din, W., Abdel-Rahman, G., Abdel-Rahman, A., Kamel, A. (2013). Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation. EKB Journal Management System, 16(1), 37-44. doi: 10.21608/scumj.2013.45665
Wael A Nasr El-Din; Gamal M Abdel-Rahman; Alaa El-Din S Abdel-Rahman; Amr A Kamel. "Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation". EKB Journal Management System, 16, 1, 2013, 37-44. doi: 10.21608/scumj.2013.45665
Nasr El-Din, W., Abdel-Rahman, G., Abdel-Rahman, A., Kamel, A. (2013). 'Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation', EKB Journal Management System, 16(1), pp. 37-44. doi: 10.21608/scumj.2013.45665
Nasr El-Din, W., Abdel-Rahman, G., Abdel-Rahman, A., Kamel, A. Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation. EKB Journal Management System, 2013; 16(1): 37-44. doi: 10.21608/scumj.2013.45665

Interleukin-10 Protects Rat Liver from CCl4-induced Fi-brogenesis via Inhibition of Hepatic Stellate Cells Activation

Suez Canal University Medical Journal
Article 5, Volume 16, Issue 1, March 2013, Page 37-44  XML PDF (209.14 K)
Document Type: Original Article
DOI: 10.21608/scumj.2013.45665
View on SCiNiTO View on SCiNiTO
Authors
Wael A Nasr El-Din email 1; Gamal M Abdel-Rahman1; Alaa El-Din S Abdel-Rahman2; Amr A Kamel3
1Department of Anatomy, Faculty of Medicine, Suez Canal University, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt
3Department of Pathology, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background: After liver injury, hepatic stellate cells (HSCs) lose vitamin A and transform into myofibroblasts (MFB), called activated HSCs, which express α-SMA and have the function of contractibility, proliferation, and fibrogenesis.IL-10 is active as an antifibrogenic drug able to reduce the α-SMA expression in ongoing fibrogenesis. Aim: To study the effect of interleukin-10 on the expression of α-smooth muscle actin (α-SMA), in hepatic stellate cells of experimental rats with hepatic fibrosis. Materials and Methods: one hundred and eight rats were divided equally into two groups: control and CCl4-treated group, which subdivided into 3 subgroups, a group immediately puts into death after treatment, spontaneous recovery (SR) group, and IL-10-treated group. Each group included 27 rats. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and albumin were assessed. Livers were taken out and processed for the expression of tissue α-smooth muscle actin (α-SMA) by immunohistochemical assay. Results:serum ALT and AST were significantly higher in rats injected with CCl4 (90.01±2.77 IU/L and 56.42±3.27 IU/L, P < 0.05 each), moderately reduced in the SR group (58.26±1.94 IU/L and 37.18±2.31IU/L, P < 0.05 each), and significantly reduced by administration of IL-10 (28.77±2.03IU/L and 37.18±2.31 IU/L, p< 0.05 each). The expression of α-SMA in the hepatic cells was strong in CCl4-induced fibrosis group compared to the control group (p< 0.05). The expressionwas moderate in the spontaneous recovery group, but less than CCl4-treated group and was significantly reduced in IL-10-treated group. Conclusions: IL-10 is an active antifibrogenic drug that reduces α-SMA expression in ongoing fibrogenesis.
 
 
Keywords
Liver fibrosis; IL-10; α-SMA
Statistics
Article View: 191
PDF Download: 343